Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020
Abstract Biomarkers can guide precision medicine in clinical trials and practice. They can increase clinical trials' efficiency through selection of study populations more likely to benefit from treatment, thus increasing statistical power and reducing sample size requirements or study duration...
Saved in:
Main Authors: | Elisabeth Bakker (Author), Viktoriia Starokozhko (Author), Jet W. M. Kraaijvanger (Author), Hiddo J. L. Heerspink (Author), Peter G. M. Mol (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2023-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe
by: Carla J. Jonker, et al.
Published: (2022) -
A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe
by: Jeroen V. Koomen, et al.
Published: (2021) -
Fuzzy Techniques for Decision Making 2018
Published: (2020) -
Navigating the uncertainty of precision cancer screening: The role of shared decision-making
by: Joseph H. Gallagher, et al.
Published: (2023) -
Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting
by: Elisabeth Bakker, et al.
Published: (2021)